US 12,465,609 B2
Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level
John Stover, Würzburg (DE); and Frank Tegtmeier, Würzburg (DE)
Assigned to veriNOS operations GmbH, Würzburg (DE)
Filed by veriNOS operations GmbH, Würzburg (DE)
Filed on May 8, 2023, as Appl. No. 18/313,920.
Claims priority of application No. 22172171 (EP), filed on May 6, 2022.
Prior Publication US 2023/0381184 A1, Nov. 30, 2023
Int. Cl. A61K 31/519 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 25/00 (2018.01); A61P 27/02 (2018.01); A61P 35/00 (2018.01)] 6 Claims
 
1. A method of treating a human patient suffering from a brain injury that is associated with an injury-induced extracellular brain glutamate level >10 μmol/L, wherein the method comprises:
selecting the human patient on the basis of a patient age of 18-39 years and a time from injury of ≤12 hours; and
intravenously administering to the patient a therapeutically effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
and/or a compound of formula (II):

OG Complex Work Unit Chemistry
for a period of 48 hours, wherein administering the therapeutically effective amount of the compound of formula (I) and/or of formula (II) results in an odds ratio for having an extracellular brain glutamate level >10 μmol/L that remains less than 1 for a period beginning at 24 hours after the start of the administration and extending to 96 hours after the start of the administration, wherein the odds ratio is determined by measuring an extracellular brain glutamate level by microdialysis of cerebrospinal fluid or brain extracellular fluid in a corresponding treatment patient population.